Connecting the use of innovative treatments and glucocorticoids with the multidisciplinary evaluation through rule-based natural-language processing: a real-world study on patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis

被引:2
|
作者
Motta, Francesca [1 ,2 ]
Morandini, Pierandrea [3 ]
Maffia, Fiore [3 ]
Vecellio, Matteo [2 ,4 ,5 ]
Tonutti, Antonio [1 ,2 ]
De Santis, Maria [1 ,2 ]
Costanzo, Antonio [1 ,6 ]
Puggioni, Francesca [7 ]
Savevski, Victor [3 ]
Selmi, Carlo [1 ,2 ]
机构
[1] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[2] IRCCS Humanitas Res Hosp, Div Rheumatol & Clin Immunol, Milan, Italy
[3] IRCCS Humanitas Res Hosp, Artificial Intelligence Ctr, Milan, Italy
[4] Univ Oxford, Wellcome Ctr Human Genet, Oxford, England
[5] Fdn Pisana Sci ONLUS, Ctr Ric Fdn Italiana Ric Artrite FIRA, Milan, Italy
[6] IRCCS Humanitas Res Hosp, Div Dermatol, Milan, Italy
[7] IRCCS Humanitas Res Hosp, Div Asthma Allergy & Personalized Med, Milan, Italy
关键词
artificial intelligence; rheumatology; inflammatory arthritis; electronic medical record (EMR); psoriatic arthritis; ARTIFICIAL-INTELLIGENCE; EUROGUIDERM GUIDELINE; SYSTEMIC TREATMENT; MANAGEMENT; RECOMMENDATIONS; VULGARIS; CARE;
D O I
10.3389/fmed.2023.1179240
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundThe impact of a multidisciplinary management of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis on systemic glucocorticoids or innovative treatments remains unknown. Rule-based natural language processing and text extraction help to manage large datasets of unstructured information and provide insights into the profile of treatment choices. MethodsWe obtained structured information from text data of outpatient visits between 2017 and 2022 using regular expressions (RegEx) to define elastic search patterns and to consider only affirmative citation of diseases or prescribed therapy by detecting negations. Care processes were described by binary flags which express the presence of RA, PsA and psoriasis and the prescription of glucocorticoids and biologics or small molecules in each cases. Logistic regression analyses were used to train the classifier to predict outcomes using the number of visits and the other specialist visits as the main variables. ResultsWe identified 1743 patients with RA, 1359 with PsA and 2,287 with psoriasis, accounting for 5,677, 4,468 and 7,770 outpatient visits, respectively. Among these, 25% of RA, 32% of PsA and 25% of psoriasis cases received biologics or small molecules, while 49% of RA, 28% of PsA, and 40% of psoriasis cases received glucocorticoids. Patients evaluated also by other specialists were treated more frequently with glucocorticoids (70% vs. 49% for RA, 60% vs. 28% for PsA, 51% vs. 40% for psoriasis; p < 0.001) as well as with biologics/small molecules (49% vs. 25% for RA, 64% vs. 32% in PsA; 51% vs. 25% for psoriasis; p < 0.001) compared to cases seen only by the main specialist. ConclusionPatients with RA, PsA, or psoriasis undergoing multiple evaluations are more likely to receive innovative treatments or glucocorticoids, possibly reflecting more complex cases.
引用
收藏
页数:9
相关论文
共 11 条
  • [1] ARTIFICIAL INTELLIGENCE TO CONNECT THE USE OF BIOLOGICS AND SMALL MOLECULES IN RHEUMATOID AND PSORIATIC ARTHRITIS WITH A MULTIDISCIPLINARY EVALUATION: A REAL WORLD EVIDENCE APPROACH THROUGH NATURAL-LANGUAGE PROCESSING
    Moranding, P.
    Maffia, F.
    Puggioni, F.
    Motta, F.
    Vecellio, M.
    Costanzo, A.
    Savevski, V.
    Selmi, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 392 - 393
  • [2] Epidemiology and Treatment of Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis in Germany: A Real-World Evidence Study
    Claudia Grellmann
    Wojciech Dombrowsky
    Volker Fabricius
    Robert Suruki
    Anna Sheahan
    Lars Joeres
    Advances in Therapy, 2021, 38 : 366 - 385
  • [3] Epidemiology and Treatment of Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis in Germany: A Real-World Evidence Study
    Grellmann, Claudia
    Dombrowsky, Wojciech
    Fabricius, Volker
    Suruki, Robert
    Sheahan, Anna
    Joeres, Lars
    ADVANCES IN THERAPY, 2021, 38 (01) : 366 - 385
  • [4] Real-world registry-based study on apremilast use in psoriasis and psoriatic arthritis in Finland
    Koskivirta, I
    Ruotsalainen, J.
    Kurki, S.
    Lakkakorpi, P.
    Salminen-Mankonen, H.
    Pirila, L.
    Harvima, R.
    Palomaki, A.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2023, 52 (05) : 549 - 555
  • [5] Real-world registry-based study on apremilast use in psoriasis and psoriatic arthritis in Finland (Jan, 10.1080/03009742.2022.2151109, 2023)
    Koskivirta, I
    Ruotsalainen, J.
    Kurki, S.
    Lakkakorpi, P.
    Salminen-Mankonen, H.
    Pirila, L.
    Harvima, R.
    Palomaki, A.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2023,
  • [6] Using natural language processing to explore characteristics and management of patients with axial spondyloarthritis and psoriatic arthritis treated under real-world conditions in Spain: SpAINET study
    Benavent, Diego
    Munoz-Fernandez, Santiago
    De la Morena, Isabel
    Fernandez-Nebro, Antonio
    Marin-Corral, Judith
    Rosa, Eva Castillo
    Taberna, Miren
    Sanabra, Cristina
    Sastre, Carlos
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2023, 15
  • [7] Real-world use of biological drugs in patients with psoriasis/psoriatic arthritis: a retrospective, population-based study of years 2010-2014 from Southern Italy
    Marciano, Ilaria
    Randazzo, Maria P.
    Panagia, Paolo
    Intelisano, Rosanna
    Sgroi, Carmela
    Ientile, Valentina
    Cannavo, Serafinella
    Guarneri, Claudio
    Reitano, Paolina
    Spina, Edoardo
    Trifiro, Gianluca
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2020, 155 (04): : 441 - 451
  • [8] Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study
    Kiltz, Uta
    Sfikakis, Petros P.
    Gaffney, Karl
    Sator, Paul-Gunther
    von Kiedrowski, Ralph
    Bounas, Andreas
    Gullick, Nicola
    Conrad, Curdin
    Rigopoulos, Dimitris
    Lespessailles, Eric
    Romanelli, Marco
    Ghislain, Pierre-Dominique
    Brandt-Juergens, Jan
    Rashkov, Rasho
    Aassi, Maher
    Orsenigo, Roberto
    Perella, Chiara
    Pournara, Effie
    Gathmann, Sven
    Jagiello, Piotr
    Veit, Justyna
    Augustin, Matthias
    ADVANCES IN THERAPY, 2020, 37 (06) : 2865 - 2883
  • [9] Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study
    Uta Kiltz
    Petros P. Sfikakis
    Karl Gaffney
    Paul-Gunther Sator
    Ralph von Kiedrowski
    Andreas Bounas
    Nicola Gullick
    Curdin Conrad
    Dimitris Rigopoulos
    Eric Lespessailles
    Marco Romanelli
    Pierre-Dominique Ghislain
    Jan Brandt-Jürgens
    Rasho Rashkov
    Maher Aassi
    Roberto Orsenigo
    Chiara Perella
    Effie Pournara
    Sven Gathmann
    Piotr Jagiello
    Justyna Veit
    Matthias Augustin
    Advances in Therapy, 2020, 37 : 2865 - 2883
  • [10] MONOTHERAPY AND FIRST LINE USE ARE ASSOCIATED WITH HIGHER JAK-INHIBITOR RETENTION RATES IN PATIENTS IN BOTH RHEUMATOID AND PSORIATIC ARTHRITIS: A RETROSPECTIVE REAL-WORLD STUDY
    Luciano, N.
    Barone, E.
    Brunetta, E.
    De Santis, M.
    Ceribelli, A.
    Caprioli, M.
    Guidelli, G. M.
    Sonaglia, A.
    Renna, D.
    Isailovic, N.
    Selmi, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 732 - 732